<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354118</url>
  </required_header>
  <id_info>
    <org_study_id>12135-12-079</org_study_id>
    <nct_id>NCT02354118</nct_id>
  </id_info>
  <brief_title>Maintaining Patency in Implanted Port Catheters</brief_title>
  <official_title>Maintaining Patency in Implanted Port Catheters With Saline Only Flushes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safest and most effective flushing solution for
      maintaining patency (unobstructed flow) in implanted port catheters. The complication rate in
      patients whose ports are flushed with saline only will be compared to the complication rate
      in patients whose ports are flushed with a combination of saline and heparinized saline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safest and most effective flushing solution for
      maintaining patency (unobstructed flow) in implanted port catheters. The complication rate in
      patients whose ports are flushed with saline only will be compared to the complication rate
      in patients whose ports are flushed with a combination of saline and heparinized saline.
      These complications include partial or complete obstruction, infection of the central line,
      and/or the onset of heparin induced thrombocytopenia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of first complete occlusion (blockage)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>The date of the first complete occlusion will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurence of first partial occlusion (blockage)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>The date of the first partial occlusion will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency with which CathFlo (alteplase) must be used to resolve an occlusion</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>The frequency CathFlo (alteplase) use to resolve an occlusion will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of complete or partial occlusions</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>The number of complete or partial occlusions after the first occurrence will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days catheter remains patent (unobstructed)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>The number of days from study enrollment to the first partial or complete occlusion and the number of days between incidences of partial or complete occlusion will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Line-Associated Blood Stream Infection (CLABSI)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Any laboratory-confirmed blood stream infection that is considered central line associated will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heparin-related complication</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Heparin Induced Thrombocytopenia (HIT) as measured by a positive HIT antibody test, or any other heparin allergy, will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Obstruction; Catheter, Infusion Catheter (Vascular)</condition>
  <condition>Catheter; Complications (Indwelling Catheter)</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heparinized saline catheter flush</intervention_name>
    <description>The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline-only catheter flush</intervention_name>
    <description>The intervention group will have their port catheters flushed with saline only.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read and understand English

          -  Has an implanted port in place less than one (1) year

          -  Evidence of a patent (unobstructed) port catheter prior to enrollment in the study

          -  Is receiving active treatment (i.e., receiving a therapeutic drug through the
             implanted port)

          -  Current treatment protocol projected to continue for a minimum of three (3) months

          -  Anticipates receiving care at the identified centers for 12 months following
             enrollment in the study

          -  Does not receive care of implanted port at any other facility

        Exclusion Criteria:

          -  Has documented heparin platelet antibody (i.e., could not be randomized to either
             group) or other allergy to heparin

          -  Receiving therapeutic dose of an anticoagulant (e.g.,warfarin, heparin, enoxaparin)

          -  Does not have a BioFlo port (heparinized port)

          -  Does not meet one or more of the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriHealth Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
    <phone>513-853-1300</phone>
    <email>Sarah_Pelgen@trihealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Baker, PhD RN</last_name>
    <phone>513-569-6191</phone>
    <email>Rachel_Baker2@trihealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Health Barrett Infusion Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Sanker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute Good Samaritan Infusion Center at GSH</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambulatory Treatment Center at Bethesda North TriHealth Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute Good Samaritan Infusion Center, Medicenter</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute Good Samaritan Infusion Center, Cheviot</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute Good Samaritan Infusion Center, Anderson</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute Good Samaritan Infusion Center Butler County</name>
      <address>
        <city>Hamilton</city>
        <state>Ohio</state>
        <zip>45011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McCullough Hyde Memorial Hospital Infusion Center</name>
      <address>
        <city>Oxford</city>
        <state>Ohio</state>
        <zip>45056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pelgen, BSN, RN, OCN</last_name>
      <phone>513-853-1300</phone>
      <email>Sarah_Pelgen@trihealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TriHealth Inc.</investigator_affiliation>
    <investigator_full_name>Rachel Baker</investigator_full_name>
    <investigator_title>Nurse Researcher</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

